Opendata, web and dolomites

GI-BCT SIGNED

Disruptive imaging technology for accurate and painless breast cancer diagnosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GI-BCT project word cloud

Explore the words cloud of the GI-BCT project. It provides you a very rough idea of what is the project "GI-BCT" about.

painful    scanned    discrimination    21    saving    estimate    prevalent    yielding    painless    form    precise    countries    first    limited    patent    avoiding    patents    hired    save    poor    service    meur    cancer    commercialization    agents    rate    missed    solid    revenue    net    granted    bct    trials    disruptive    entering    healthcare    formed    demonstrated    start    dense    mammography    machinery    environment    disease    images    clinical    contrast    discovered    computed    outcomes    recalls    amount    ready    scientific    routing    sold    compression    5m    combines    gratxray    sales    women    roi    3d    56    procedure    patients    15    therapeutic    reduce    efficient    detection    profits    gi    centers    survival    employees    team    2021    performing    85b    false    screening    beur    programs    stage    grating    patient    later    treatment    die    imaging    207    portfolio    investment    potentially    natural    59    q1    breast    breasts    size    400    positives    mortality    unnecessary    contracts    interferometry    tissue    resolution    industry    68    lowering    2d    market    640    95    produces    provides    tomography    worked   

Project "GI-BCT" data sheet

The following table provides information about the project.

Coordinator
GRATXRAY AG 

Organization address
address: PARK INNOVAARE
city: VILLIGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gratxray.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GRATXRAY AG CH (VILLIGEN) coordinator 50˙000.00

Map

 Project objective

Breast cancer is the most prevalent form of cancer in women, as 1 in 9 women are affected and 1 in 30 will die from the disease. Early detection is essential to reduce the mortality, thus countries have established routing screening programs. The problem is that main screening procedure of mammography is painful for patients, produces high rate of false positives for women with dense breast tissue, provides limited contrast, low-resolution and poor tissue discrimination properties. False positives lead to performing unnecessary therapeutic procedures. Also cancer in dense breasts is missed out by mammography, lowering survival outcomes when discovered in later stage. GratXray is entering the 3,56 BEUR size breast imaging market with our disruptive grating interferometry-based breast computed tomography – GI-BCT technology. GI-BCT will provide painless, efficient and precise breast cancer imaging. The breast will be scanned in its natural state in 3D, without compression and contrast agents, yielding images with a much higher contrast and better resolution. Thus saving €1,85B in healthcare costs in Europe and US by avoiding recalls, €640 000 from machinery costs for breast centers and potentially save treatment costs in the amount of €95 000 per patient. We have worked for the past 15 years in GI-BCT research and have a solid patent portfolio of 8 granted patents. Currently, we have demonstrated our technology in operational environment, and we are ready to start first clinical trials in 2D with the goal to make first sales in Q1 2021. We have formed a team that combines strong scientific, industry and user know-how. We estimate that a further investment of €5M and 3 years is required to reach the commercialization stage. We estimate that in year 6 we have hired 50 employees, sold 59 systems per year, have 207 service contracts, revenue of 68 MEUR, net profits of 21 MEUR and reach ROI of 4 (400%).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GI-BCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GI-BCT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More